Publications

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.

Moore SC. et al, (2023), Med (N Y)

Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.

Vatzia E. et al, (2023), NPJ Vaccines, 8

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster

Ulaszewska M. et al, (2023), Human Vaccines & Immunotherapeutics

Divergent trajectories of antiviral memory after SARS-CoV-2 infection

Tomic A. et al, (2022), Nature Communications, 13

Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro.

Nyagwange J. et al, (2022), International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.

Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

Shaw RH. et al, (2022), The Lancet Respiratory Medicine, 10, 1049 - 1060

Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.

Foster WS. et al, (2022), Cell reports. Medicine

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

Mentzer AJ. et al, (2022), Nature Medicine

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.

Fidler S. et al, (2022), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.

Madhi SA. et al, (2022), The Lancet. Infectious diseases

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Madhavan M. et al, (2022), eBioMedicine, 104298 - 104298

Risk factors for Crimean-Congo Haemorrhagic Fever (CCHF) virus exposure in farming communities in Uganda.

Atim SA. et al, (2022), The Journal of infection

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants

van Doremalen N. et al, (2022), Nature Communications, 13

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

McNaughton AL. et al, (2022), JCI Insight, 7

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

Marchevsky NG. et al, (2022), eBioMedicine, 81, 104128 - 104128

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Liu X. et al, (2022), The Journal of infection, 84, 795 - 813

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.

Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.

Li G. et al, (2022), Lancet (London, England), 399, 2212 - 2225

Viral vector vaccines.

McCann N. et al, (2022), Current opinion in immunology, 77

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.

Munro APS. et al, (2022), The Lancet. Infectious diseases

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ogbe A. et al, (2022), JCI Insight, 7

Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.

Ratcliff J. et al, (2022), Journal of clinical microbiology

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination

Sharpe HR. et al, (2022), JCI Insight, 7

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

Spencer AJ. et al, (2022), eBioMedicine, 77, 103902 - 103902

Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.

van Doremalen N. et al, (2022), Res Sq

Response to Letter to the Editor by Ish et al. entitled ‘COVID-19 vaccine equity—the need of the hour’

Maclean P. et al, (2022), QJM: An International Journal of Medicine

Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.

Waerlop G. et al, (2022), Frontiers in immunology, 13

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

Ogbe A. et al, (2021), Nature Communications, 12

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu C. et al, (2021), Cell, 184, 4220 - 4236.e13

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey M. et al, (2021), The Lancet, 397, 881 - 891

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2021), The Lancet, 397, 99 - 111

Cookies on this website

Publications